Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus pembrolizumab in advanced or metastatic hepatocellular carcinoma after prior PD-1/PD-L1 therapy
jRCT2031200435Completed
- Sponsor
- Bayer
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Open-label, single-arm trial of regorafenib and pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Objective response rate (central, RECIST 1.1a). Started Apr 2021; status: completed.
02
Drugs
regorafenibpembrolizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2031200435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200435.